Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cidofovir for BK Virus Nephropathy in Renal Transplant Recipients
NCT00138424Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2006
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cidofovir in BK virus nephropathy (BKVN) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety and Tolerability of Cidofovir Assessed by Enumeration of Adverse Events Per Subject, Changes Observed in the Physical Examination and 1 more. Started May 2006; status: terminated.
02
Drugs
cidofovir
03
Conditions
BK virus nephropathy (BKVN)
Beyond the preview
Go deeper on NCT00138424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00138424.